SCHEMBL18711516

SCHEMBL18711516

CC(=O)N1CCN(S(=O)(=O)c2ccccc2Cl)CC1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.62
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
FAAH O00519 5/20 0.53
CHRM4 P08173 3/20 0.52
CNR1 P21554 1/20 0.51
HDAC3 O15379 1/20 0.49
HDAC4 P56524 1/20 0.49
HDAC1 Q13547 1/20 0.49
HDAC7 Q8WUI4 1/20 0.49
HDAC2 Q92769 1/20 0.49
HDAC10 Q969S8 1/20 0.49
HDAC11 Q96DB2 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
HDAC9 Q9UKV0 1/20 0.49
HDAC5 Q9UQL6 1/20 0.49
MAPT P10636 1/20 0.49
MAPK1 P28482 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2955778 0.87 FAAH (0.57) MEN1KMT2AFAAHCHRM4CNR1
SCHEMBL18701981 0.86 CNR1 (0.53) ALDH1A1MEN1KMT2AFAAHCHRM4
SCHEMBL10723724 0.86 CHRM4 (0.64) ALDH1A1MEN1KMT2AFAAHCHRM4
SCHEMBL15830167 0.86 ALDH1A1 (0.53) ALDH1A1MEN1KMT2AMAPK1
SCHEMBL15916798 0.84 GPR183 (0.57) ALDH1A1MEN1KMT2A
SCHEMBL18711918 0.84 ALDH1A1 (0.67) ALDH1A1MEN1KMT2AMAPK1
SCHEMBL18711450 0.84 CNR1 (0.68) ALDH1A1MEN1KMT2ACNR1MAPT
SCHEMBL20267592 0.83 MMP2 (0.55) ALDH1A1MEN1KMT2AMAPK1
SCHEMBL15935220 0.83 KMT2A (0.56) ALDH1A1MEN1KMT2AMAPT
SCHEMBL13239816 0.83 TGM2 (0.59) FAAHMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3356345-B1 HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS MAX PLANCK GESELLSCHAFT (DE) 2023-11-08 EP disclosed
US-20170096435-A1 SEPIAPTERIN REDUCTASE INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) 2017-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170096435-A1 SEPIAPTERIN REDUCTASE INHIBITORS SPR, QDPR, SRR ALDH1A1 374/4885MEN1 4876/4885KMT2A 2884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.